H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on GH Research (GHRS – Research Report) today and set a price target of $45.00. The company’s shares closed yesterday at $10.17.
According to TipRanks, Trucchio is an analyst with an average return of -17.9% and a 30.95% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Immunocore Holdings, and Arrowhead Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for GH Research with a $37.40 average price target, which is a 267.75% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $49.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $17.41 and a one-year low of $5.70. Currently, GH Research has an average volume of 69.14K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Read More on GHRS:
